

# Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19

1 Minghua Jiang<sup>1\*</sup>, Weihua Pan<sup>2\*</sup>, Amir Aratehfar<sup>3\*</sup>, Wenjie Fang<sup>2</sup>, Liyan Ling<sup>4</sup>, Hua Fang<sup>5</sup>,  
2 Farnaz Daneshnia<sup>3</sup>, Jian Yu<sup>1</sup>, Wanqing Liao<sup>2</sup>, Hao Pei<sup>6#</sup>, Xiaojing, Li<sup>7#</sup>, Cornelia Lass-Flörl<sup>8</sup>

3 <sup>1</sup> Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's  
4 Hospital of Wenzhou Medical University, Wenzhou, China;

5 <sup>2</sup> Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Institute of Mycology,  
6 Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China;

7 <sup>3</sup> Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands;

8 <sup>4</sup> Department of Laboratory Medicine, Pinghu Second People's Hospital, Zhejiang, China;

9 <sup>5</sup> Department of Laboratory Medicine, Pudong New Area People's Hospital, Shanghai, China;

10 <sup>6</sup> Department of Laboratory Medicine, Wuxi No. 5 People's Hospital, Jiangsu, China;

11 <sup>7</sup> Department of Dermatology, Affiliated Hospital of Hebei University of Engineering, Hebei, China;

12 <sup>8</sup> Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck,  
13 Austria

14 \*Minghua Zhu, Weihua Pan and Amir Aratehfar equally contributed to this study.

## 15 \* Correspondence:

16 Xiaojing Li, Tel: +8615000632735, Fax: 86-021-81885502, Email: [zlmsh@126.com](mailto:zlmsh@126.com)

17 Hao Pei, Tel: 86-0510-68585555, Fax: 86-0510-68585555, Email: [peihao1008@126.com](mailto:peihao1008@126.com)

18 Keywords: RT-LAMP, COVID-19, qRT-PCR, and SARS COV-2

## 19 Abstract

20 **Objectives:** Development and validation of a single-step and accurate reverse transcriptase loop-  
21 mediated isothermal amplification technique (RT-LAMP) for rapid identification of SARS COV-2  
22 relative to commercial quantitative reverse transcriptase real-time PCR (qRT-PCR) assays to allow  
23 prompt initiation of proper medical care and containment of virus spread.

24

25 **Methods:** Primers showing optimal *in-silico* features were subjected to analytical sensitivity and  
26 specificity to assess the limit of detection (LOD) and cross-reaction with closely- and distantly-  
27 related viral species, and clinically prominent bacterial and fungal species. In order to evaluate the  
28 clinical utility, our RT-LAMP was subjected to a large number of clinical samples, including 213  
29 negative and 47 positive patients, relative to two commercial quantitative RT-PCR assays.

30

31 **Results:** The analytical specificity and sensitivity of our assay was 100% and 500 copies/ml when  
32 serial dilution performed in both water and sputum. Subjecting our RT-LAMP assay to clinical  
33 samples showed a high degree of specificity (99.5%), sensitivity (91.4%), positive predictive value  
34 (97.7%), and negative predictive value (98.1%) when used relative to qRT-PCR. Our RT-LAMP  
35 assay was two times faster than qRT-PCR and is storable at room temperature. A suspected case that  
36 later became positive tested positive using both our RT-LAMP and the two qRT-PCR assays, which  
37 shows the capability of our assay for screening purposes.

38

39 **Conclusions:** We present a rapid RT-LAMP assay that could extend the capacity of laboratories to  
40 process two times more clinical samples relative to qRT-PCR and potentially could be used for high-  
41 throughput screening purposes when demand is increasing at critical situations.

42

## 43 **1 Introduction**

44 A new virus causing pneumonia-like infection, COVID-19, which was found in Wuhan, Hubei  
45 Province, China, and to be linked to a seafood market has caused a serious crisis worldwide (1).  
46 Almost two months after the first report, COVID-19 severe outbreaks were reported in numerous  
47 countries and became a public health priority in the world (World Health Organization, Situation  
48 Report 48). As of March 17, 2020, COVID-19 cases are found in 150 countries/regions and infected  
49 167,515 patients, among whom 6,606 died (World Health Organization, Situation Report 56). The  
50 latest phylogenetic analysis studies designated the etiologic agent of COVID-19, SARS COV-2 (2).

51 The virulent nature of this virus and its high rate of transmissibility warrants robust, rapid, sensitive,  
52 specific, and quantitative diagnostic tools to supplement clinical symptoms aiding clinicians to  
53 confidently rule in and rule out patients. Moreover, such a diagnostic tool will help with preventing  
54 spread of virus by identifying the infected cases and can monitor the health status of infected patients  
55 by quantifying the viral load. Center for Disease Control was the first to develop a quantitative  
56 reverse transcriptase real-time PCR (RT-PCR), which later became the gold standard technique  
57 (<https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html>). Subsequently, a Chinese group  
58 used a RNA-based metagenomics next generation sequencing (mNGS) to diagnose the viral RNA  
59 from the clinical samples of two patients (3). However, the requirement for advanced technology and  
60 skilled personnel and long turn-around time (24 hours) are not feasible for local and referral  
61 laboratories. Therefore, a colorimetric loop mediated isothermal amplification, also known as LAMP,  
62 was developed to obviate the need for expensive technologies, e.g. real-time PCR and NGS, as well  
63 as to shorten the turn-around time to up to 40 minutes (4). However, this assay was a qualitative one  
64 and also only the swab samples from limited number of patients ( $n=7$ ) were included for testing (4).  
65 Most recently a newer generation of single step RT-LAMP were developed to detect SARS COV-2,  
66 but these assays were not challenged with real clinical samples obtained from COVID-19 positive  
67 patients (5, 6). Therefore, we developed a sensitive, specific, and rapid RT-LAMP assay and its  
68 performance was challenged by an extensive number of confirmed COVID-19 ( $n=47$ ) and negative  
69 patients ( $n=213$ ) relative to qRT-PCR assays approved by two Chinese Food and Drug  
70 Administration (qRT-PCR NMPA). Altogether, we present a rapid and reliable diagnostic tool that  
71 potentially could be deployed for high-throughput screening applications in referral and local  
72 laboratories.

## 73 **2 Materials and methods**

### 74 **Target selection**

75 According to *Guidelines for prevention and control of Covid-19 (Fourth Edition)* issued by National  
76 Health Commission of the PRC on 2020.2.26, open reading frame 1ab (ORF1ab) or nucleocapsid  
77 protein (N) were recommended for designing diagnostic assays detecting SARS-HCoV-2 from  
78 clinical samples. Therefore, ORF1ab and N sequences of SARS-Cov-2, its close related coronavirus  
79 species (HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1), and other viral species,  
80 namely Adenovirus, Respiratory syncytial virus A, Human parainfluenza 2 virus, Human  
81 parainfluenza 3 virus, H1N1 influenza virus, H5N1 influenza virus, H7N9 influenza virus, H9N2  
82 influenza virus, Mycoplasma pneumoniae and Influenza B virus, were downloaded from GenBank  
83 (<https://www.ncbi.nlm.nih.gov/genbank/>) to select the most specific target region. Genious  
84 v11.1.14 was used for alignment analysis and to find the most specific region for designing LAMP  
85 primers. LAMP Designer (PREMIER Biosoft International, San Francisco, CA) was used for primer  
86 design. Designed primers were subjected to BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) and the  
87 specific candidates were used for analytical sensitivity and specificity testing (Table 1). Primers were  
88 synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).

### 89 **Analytical sensitivity and specificity testing**

90 Analytical sensitivity and specificity testing was performed in a P2 lab and in order to mimic the real  
91 viral particles we purchased pseudotyped SARS-CoV-2 assay system containing ORF1ab part  
92 sequence, N gene and E gene (DAAN gene Co. Ltd, Guangzhou, China). RNA of pseudotyped virus  
93 were extracted using EZ-10 Spin Column Viral Total RNA Extraction Kit (Sangon Biotech Co.,Ltd.  
94 Shanghai, China). Serial dilutions with the magnitude of  $\log_{10}$  containing  $50 \times 10^6$  cell/ml to  $50 \times 10^0$   
95 cell/ml pseudotyped virus were performed to determine the limit of detection (LOD). Serial dilution  
96 testing was performed in both RNase/DNase free molecular grade water and sputum sample collected  
97 from a COVID-19 negative healthy individual. Reproducibility of our LAMP assay (linearity= $R^2$   
98 value) was assessed by separate serial dilution testing on three occasions, each performed in duplicate.

99 Signal intensity and the time to obtain decent amplification curves were recorded and  $R^2$  values  
100  $\geq 0.98$  were considered reliable amplification.

101 Specificity testing included nucleic acid of HCoV-OC43 , HCoV-HKU1 , HCoV-229E , HCoV-  
102 NL63, Adenovirus, Respiratory syncytial virus A, Human parainfluenza 2 virus, Human  
103 parainfluenza 3 virus, H1N1 influenza virus, H5N1 influenza virus, H7N9 influenza virus, H9N2  
104 influenza virus, Mycoplasma pneumoniae, Influenza B virus (Bdsbiotech Co. Ltd, Guangzhou,  
105 China). Moreover, HeLa cells (TechStar Co. Ltd, Jiangsu, China) and genomic DNA of clinically  
106 prominent bacteria or fungal species, including *Staphylococcus aureus*, *Mycobacterium tuberculosis*,  
107 *Legionella pneumophila*, *Candida albicans*, *Candida glabrata*, *Candida tropicalis*, *Aspergillus*  
108 *fumigatus*, *Cryptococcus neoformans* were used for specificity testing (provided by Shanghai  
109 Institute of Medical Mycology, Shanghai Changzheng hospital). LAMP incubation time was set to 60  
110 minutes to observe both limit of detection and cross-reactivity (LAMP conditions are mentioned in  
111 clinical evaluation section). The reaction endpoint time was set in a way to detect the lowest possible  
112 copy number of virus without any cross-reaction.

### 113 **Evaluating LAMP assay tolerance against wide range of inhibitors**

114 Clinical samples obtained from patients contain a wide range of inhibitors impairing the efficacy of  
115 diagnostic assay. Therefore, the tolerance of our LAMP assay was assessed when 500 copy/ml of  
116 simulated viral particles were mixed with human blood, mucin,  $\beta$ -adrenergic bronchodilator, Tamiflu,  
117 dexamethasone, adrenaline.

### 118 **Clinical validation**

119 Clinical validation engaged two clinical centers, namely The Second Affiliated Hospital and Yuying  
120 Children's Hospital of Wenzhou Medical University, Wenzhou, China (Center one), and the Wuxi

121 Infectious Diseases Hospital, Wuxi, China (Center two). Each center used a different qRT-NMPA  
122 assay as a gold standard technique. SARS-CoV-2 kit from Shanghai BioGerm Medical  
123 Biotechnology Co. Ltd, (NMPA approval number 20203400065, with LOD of 1000 copies/ml, Ct  
124 cut-off 38), and a kit from DAAN Gene Co., Ltd (NMPA approval number 20203400063, with LOD  
125 of 500 copies/ml, cut off Ct value of 40) were used in center one and center two, respectively.  
126 Positive patients were divided into two groups by physicians, namely suspected and confirmed.  
127 Those suspected were isolated and all became positive. The ethics committees of both centers  
128 approved the study. Emergency patients (outpatients) with fever of unknown origin or inpatients  
129 diagnosed as COVID-19 or other diseases were enrolled and samples such as sputum, swabs and  
130 tears were used for evaluation. ABI 7500 were used for amplification and data analysis in both  
131 centers.

132 The final LAMP reaction was 25  $\mu$ l and contained 21.9  $\mu$ l buffer solution (20 mM Tris-HCl pH 8.8,  
133 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 120 mM KCl, 2 mM MgSO<sub>4</sub>, 0.1% Tween 20), 8 U Bst DNA polymerase (New  
134 England Biolabs (Beijing) ltd, Beijing, China), 0.5 U AMV Reverse Transcriptase (Takara Bio Inc,  
135 Dalian, China), 2  $\mu$ l RNA template, 1.6  $\mu$ M FIP/BIP primers, 0.2  $\mu$ M F3/B3 primers, 0.4  $\mu$ M LF/LB  
136 primers, 7 mM MgSO<sub>4</sub> (Sangon Biotech Co., Ltd., Shanghai, China), 0.8M betaine (Sangon Biotech  
137 Co., Ltd., Shanghai, China), 1.4 mM each dNTP (Takara Bio Inc, Dalian, China), 0.5  $\mu$ M SYTO-9  
138 (Invitrogen Trading, Shanghai) Co., Ltd, Shanghai, China). LAMP reactions were incubated at 63°C  
139 for 30 mins in ABI 7500 machine and florescent data were collected each minute. RT-PCR and RT-  
140 LAMP tested separately by two assessors, final results were recorded and were compared with one  
141 another.

### 142 **3 Results and discussion**

143 The whole workflow of our study from *in-silico* analysis to analytical evaluation and clinical  
144 validation is depicted in Figure 1. Nine and six LAMP primer systems were designed and evaluated  
145 *in-silico*, but only the six primers showed the highest sensitivity and specificity, which used in the  
146 next steps (Table 1). Primarily, our assay was meant to be quantitative and it showed an optimal  
147 reproducibility when tested in analytical evaluation step using armored viral particle diluted in water  
148 ( $R^2$  value  $\square$ 0.99) and sputum sample ( $R^2$  value  $\square$ 0.83). Analytical sensitivity yielded reliable LOD of  
149 500 copies/ml less than 30 minutes regardless of matrix used for serial dilution (Figure 1). Of note,  
150 our assay could detect 50 copies/ml, but some replicates showed unstable amplification. Therefore,  
151 we considered the LOD of 500 copies/ml. Analytical specificity was 100% when used a wide range  
152 of closely- and distantly-related viral species, prominent fungal and bacterial species, and human  
153 DNA. Moreover, analytical evaluation included a wide range of inhibitors and 500 copies of the  
154 simulated viral particles were successfully detected below 30 minutes (Figure 1). In order to evaluate  
155 the performance of our assay in clinic, we provided our assay and respective instructions to two  
156 clinical centers (Figures 1, 2). In total, 168 patients from center 1, among which 35 confirmed  
157 COVID-19 cases, and 92 patients from center 2, among which 12 patients were confirmed COVID-  
158 19 cases, were recruited. One asymptomatic patient tested positive by qRT-PCR (Ct values 37) and  
159 by our RT-LAMP was categorized suspected by in-charge physician and few days later became  
160 positive. Four patients tested positive by qRT-PCR were negative by our RT-LAMP and one patient  
161 tested negative by qRT-PCR was positive by our assay (Figure 1 and Supplementary Table 1).  
162 Subsequently, our RT-LAMP assay showed the sensitivity, specificity, negative predictive value, and  
163 positive predictive value of 91.4%, 99.5%, 98.1%, and 97.7%, respectively (Supplementary Table 2  
164 and 3). The fact that our assay could not detect four positive patients was owing to using 2.5 less  
165 RNA input (2  $\mu$ l) relative to qRT-PCR (5  $\mu$ l). In the future, we will try to use various RNA input  
166 volume (5, 8, and 10  $\mu$ l) to observe if we could obtain a higher sensitivity. Although our RT-LAMP  
167 assay was developed to be quantitative, we could not find any pattern and association between the

168 time to positivity by our RT-LAMP assay and the Ct values reported by qRT-PCR when using  
169 clinical samples. Therefore, we considered our assay a qualitative one. This fact will show that the  
170 analytical valuation should be always accompanied by clinical validation to observe the real  
171 capabilities of a given assay and that the results obtained in analytical evaluation step are not always  
172 reflected in real-life.

173 Our assay has several advantageous compared to qRT-PCR. First, our RT-LAMP assay is two times  
174 faster relative to qRT-PCR (Figure 2) and given the optimal diagnostic features could be used as a  
175 reliable screening method in local and referral laboratory to keep up with the increasing demand of  
176 suspected patients in critical situations. Secondly, our assay does not need the clod chain and could  
177 be shipped at room temperature (Figure 2).

178 In conclusion, we present a rapid RT-LAMP assay that allows processing 2 to 2.5 more clinical  
179 samples relative to CDC RT-PCR, which is indicative of its capacity to be deployed for high-  
180 throughput screening applications in local and referral laboratories.

181 We admit that our assay does not has the quantitative aspect of qRT-PCR and its sensitivity requires  
182 improvement. These two limitations will be the subject of future investigation. Moreover, we will try  
183 to use simple and fast nucleic acid extraction procedures (7) that only uses heat that will further  
184 decrease the turn-around-time.

### 185 **Ethics Statement**

186 The protocol was approved by the Ethics and Research Committee of The Second Affiliated Hospital  
187 and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China, and the Wuxi  
188 Infectious Diseases Hospital, Wuxi, China

### 189 **Figures**

190 Figure 1. Our assay was comprehensively evaluated at three steps, including in-silico analysis, in-  
191 vitro analytical analysis, and clinical validation.

192 Figure 2. Workflow comparison of our RT-LAMP assay relative to qRT-PCR for emergency cases  
193 (outpatients) and inpatients. Our RT-LAMP assay is 2 to 2.5 times faster than the qRT-PCR assays  
194 and can be shipped at room temperature.

## 195 **Tables**

196 Table 1. Primers and probes successfully detected SARS COV-2.

Target loci	Primer name	Primer sequence
Nucleocapsid protein	nCoV-N-F3	CCAGAATGGAGAACGCAGTG
	nCoV-N-B3	CCGTCACCACCACGAATT
	nCoV-N-FIP	AGCGGTGAACCAAGACGCAGGGCGCGATC AAAACAACG
	nCoV-N-BIP	AATTCCTCGAGGACAAGGCGAGCTCTTCG GTAGTAGCCAA
	nCoV-N-LF	TTATTGGGTAAACCTTGGGGC
	nCoV-N-LB	TTCCAATTAACACCAATAGCAGTCC

197

## 198 **Conflict of Interest**

199 *The authors declare that the research was conducted in the absence of any commercial or financial*  
200 *relationships that could be construed as a potential conflict of interest.*

## 201 **Author Contributions**

202 JMH, PWH and AA participated in primer design, LAMP optimization, data collection, and drafted  
203 the manuscript. LXJ and PH participated in designing this study and revising the manuscript. WJF,  
204 LLY, FH participated in collecting clinical samples. All authors contributed to the writing of the final  
205 manuscript.

## 206 **Funding**

207 This work was supported by the Shanghai Sailing Program (19YF1448000), the Major National  
208 R&D Projects of the National Health Department (2018ZX10101003), National Natural Science  
209 Foundation of China (31770161), Shanghai Science and Technology Committee (grant numbers

210 17DZ2272900 and 14495800500), Shanghai Municipal Commission of Health and Family Planning  
211 (2017ZZ01024-001).

## 212 Reference

- 213 1. Ma X, Ph D, Wang D, Ph D, Xu W, Wu G, Gao GF, Phil D, Tan W, Ph D. 2020. A Novel  
214 Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine* 727–  
215 733.
- 216 2. Wu Y, Ho W, Huang Y, Jin D, Li S, Liu S, Liu X, Qiu J, Sang Y, Wang Q, Yuen K, Zheng Z.  
217 2020. SARS-CoV-2 is an appropriate name for the new coronavirus. *The Lancet* 6736:2–3.
- 218 3. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, Sun Z, Liu F, Wu K, Zhong B, Mei Y, Zhang  
219 W, Chen Y. 2020. RNA based mNGS approach identifies a novel human coronavirus from two  
220 individual pneumonia cases in 2019 Wuhan outbreak. *Emerging microbes & infections* 1751.
- 221 4. Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, Tanner NA, Tanner N. 2020.  
222 Rapid Molecular Detection of SARS-CoV-2 (COVID-19 ) Virus RNA 2.
- 223 5. Park G, Ku K, Beak S, Kim SJ, Kim S Il, Kim B. 2020. Development of Reverse  
224 Transcription Loop-mediated Isothermal Amplification (RT-LAMP ) Assays Targeting SARS-CoV-  
225 2.
- 226 6. Lamb LE, Bartolone SN, Ward E, Chancellor MB. 2020. Rapid Detection of Novel  
227 Coronavirus (COVID-19 ) by Reverse Transcription- Loop-Mediated Isothermal Amplification.
- 228 7. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner  
229 MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern  
230 S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC.  
231 2018. Field-deployable viral diagnostics using CRISPR-Cas13. *Science* 360:444–448.

## 232 Supplementary Material

233 **Appendix Table 1.** Signal intensity and time corresponded to each serial dilution obtained during three separate  
234 experiments. Each experiment was performed in duplicate.

235 **Appendix Table 2.** False positive and false negative results reported by our RT-LAMP assay, when compared to  
236 qRT-PCR.

237 **Appendix Table 3.** Diagnostic feature of our RT-LAMP assay when compared to qRT-PCR.



238



# Emergency patient



# Inpatients



medRxiv preprint doi: <https://doi.org/10.1101/2020.03.15.20036376>; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

# Analytical evaluation


Target selection and LAMP design

Analytic specificity test

Cross-reaction with other viral species, bacteria, fungal species and human DNA was evaluated

Analytic sensitivity test

Armored RNA particles in **water**




Serial dilution  $5 \times 10^6$  - 5 cells/ml

LOD (500 cells/ml)  
Stability test

$y = -0.4571x + 9.4629$   
 $R^2 = 0.9896$

Armored RNA particles in **sputum**




Serial dilution  $5 \times 10^6$  - 5 cells/ml

LOD (500 cells/ml)  
Stability test


$y = -0.2263x + 7.5615$   
 $R^2 = 0.8271$

# Clinical validation

Center one



Center two



LAMP	NMPA RT-PCR 1#	
	+	-
+	32	0
-	3	133

LAMP	NMPA RT-PCR 2#	
	+	-
+	11	1
-	1	79

medRxiv preprint doi: <https://doi.org/10.1101/2020.03.27.20071000>; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.